Abstract
Ovarian cancer is the ninth most common cancer amongst women and ranked as fifth in terms of the cause of cancer related mortality accounting for more deaths than any other cancer of the female reproductive system. Gemcitabine is the most common chemotherapeutic agent used in the treatment of ovarian cancer despite of its disadvantage of having a very lesser half life. In this study, we have envisaged the use of a highly porous, biomimetic and implantable pectin scaffold embedded with gemcitabine loaded fibrin nanoconstructs to improve the half life of the drug, thereby providing localized therapy for ovarian cancer. The controlled and sustained release of the chemokine from the scaffold system was extensively analyzed in vitro different pH environments. The composite scaffolds were found to be highly biocompatible when tested with mammalian cell lines. The excellent cytotoxicity and apoptosis responses induced in ovarian cancer, PA- 1 cell lines proved that the nanocomposite Pectin scaffolds loaded with specific chemokine can be used as implantable “therapeutic wafers” for distracting metastatic cancer cells and thus improve the survival rate of ovarian cancer afflicted individuals.
Keywords: Pectin scaffolds, Fibrin nanoconstructs, Gemcitabine, Drug delivery, Ovarian cancer.
Current Drug Delivery
Title:Potential Use of Drug Loaded Nano Composite Pectin Scaffolds for the Treatment of Ovarian Cancer
Volume: 10 Issue: 3
Author(s): Sarika Chandran, G. Praveen, K.S. Snima, Shantikumar V. Nair, K. Pavithran, Krishnaprasad Chennazhi and Vinoth-Kumar Lakshmanan
Affiliation:
Keywords: Pectin scaffolds, Fibrin nanoconstructs, Gemcitabine, Drug delivery, Ovarian cancer.
Abstract: Ovarian cancer is the ninth most common cancer amongst women and ranked as fifth in terms of the cause of cancer related mortality accounting for more deaths than any other cancer of the female reproductive system. Gemcitabine is the most common chemotherapeutic agent used in the treatment of ovarian cancer despite of its disadvantage of having a very lesser half life. In this study, we have envisaged the use of a highly porous, biomimetic and implantable pectin scaffold embedded with gemcitabine loaded fibrin nanoconstructs to improve the half life of the drug, thereby providing localized therapy for ovarian cancer. The controlled and sustained release of the chemokine from the scaffold system was extensively analyzed in vitro different pH environments. The composite scaffolds were found to be highly biocompatible when tested with mammalian cell lines. The excellent cytotoxicity and apoptosis responses induced in ovarian cancer, PA- 1 cell lines proved that the nanocomposite Pectin scaffolds loaded with specific chemokine can be used as implantable “therapeutic wafers” for distracting metastatic cancer cells and thus improve the survival rate of ovarian cancer afflicted individuals.
Export Options
About this article
Cite this article as:
Chandran Sarika, Praveen G., Snima K.S., Nair Shantikumar V., Pavithran K., Chennazhi Krishnaprasad and Lakshmanan Vinoth-Kumar, Potential Use of Drug Loaded Nano Composite Pectin Scaffolds for the Treatment of Ovarian Cancer, Current Drug Delivery 2013; 10 (3) . https://dx.doi.org/10.2174/1567201811310030009
DOI https://dx.doi.org/10.2174/1567201811310030009 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Novel Therapeutic Strategies for Dementia
CNS & Neurological Disorders - Drug Targets Meet Our Editorial Board Member:
The Natural Products Journal Genetic Predisposition to Parkinson’s Disease and Cancer
Current Cancer Drug Targets Insights into Ecto-5’-Nucleotidase as a New Target for Cancer Therapy: A Medicinal Chemistry Study
Current Medicinal Chemistry Unmet Needs in Ovarian Cancer: Dividing Histologic Subtypes to Exploit Novel Targets and Pathways
Current Cancer Drug Targets Exploring the Role of Phytochemicals as Potent Natural Photosensitizers in Photodynamic Therapy
Anti-Cancer Agents in Medicinal Chemistry Superparamagnetic Iron Oxide Nanoparticles (SPIONs) for Diagnosis and Treatment of Breast, Ovarian and Cervical Cancers
Current Drug Metabolism The Mitochondrial Thioredoxin is Required for Liver Development in Zebrafish
Current Molecular Medicine Pharmacogenetics of Metabolic Genes of Anthracyclines in Acute Myeloid Leukemia
Current Drug Metabolism Effect of Cytostatic Drugs on the mRNA Expression Levels of Ribonuclease κ in Breast and Ovarian Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Kinase Phosphorylation-based Mechanisms of PARP Inhibitor Resistance During Synthetic Lethal Oncotherapy
Current Signal Transduction Therapy Anti-Tumor Effects of Osthole on Different Malignant Tissues: A Review of Molecular Mechanisms
Anti-Cancer Agents in Medicinal Chemistry PD-1/PD-Ls: A New Target for Regulating Immunopathogenesis in Central Nervous System Disorders
Current Drug Delivery 1,3,4-Thiadiazole Based Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Cell Proliferation and Cytotoxicity Assays
Current Pharmaceutical Biotechnology Structural Basis for Binding of Aurora-A<sup>G198N</sup>- INCENP Complex: MD Simulations and Free Energy Calculations
Protein & Peptide Letters Meet Our Editorial Board Member
Current Nanomedicine Trends in the Exploration of Anticancer Targets and Strategies in Enhancing the Efficacy of Drug Targeting
Current Molecular Pharmacology NOB1: A Potential Biomarker or Target in Cancer
Current Drug Targets The Genetic and Epigenetic Effects of 5-Azacytidine and its Major Breakdown Product Guanylurea
Epigenetic Diagnosis & Therapy (Discontinued)